Clinical Trials
26
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1887
Active, not recruiting
1
3.9%
Completed
9
34.6%
Recruiting
9
34.6%
Terminated
2
7.7%
Unknown
4
15.4%
Withdrawn
1
3.9%
No approval data available
- Novonesis is partnering with Metropolitan Community College in Omaha to shape a new biotechnology technician training program and launch the Novonesis Biomanufacturing Pathways Scholarship. - Nebraska bioscience employment grew 6.3% from 2019 to 2023, outpacing the state's 2.9% overall private-sector growth, underscoring demand for skilled workers. - The initiative includes a 15-week Biotechnology Fundamentals Microcredential, a Biotechnology Career Certificate, job shadowing, facility tours, and recruiter screening for graduates. - The Nebraska effort is part of a broader national strategy spanning K-12 outreach, community college partnerships, and university research collaborations across 14 North American sites.
- Nearly 40% of adult blacklegged ticks collected from residential yards in Biltmore Forest, North Carolina, tested positive for Borrelia burgdorferi, the bacterium that causes Lyme disease. - The infection rate is comparable to parts of the Northeast, mid-Atlantic, and upper Midwest where Lyme disease is long established, signaling a southward expansion of the tick vector. - Researchers also detected Borrelia miyamotoi and Anaplasma phagocytophilum, possibly the farthest south these pathogens have been identified in blacklegged tick populations. - A diagnostic gap persists because many regional clinicians were trained when Lyme disease was considered absent from North Carolina, delaying timely diagnosis and treatment.
- The Gates Foundation has awarded $13.5 million across multiple projects to reduce monoclonal antibody manufacturing costs from the current $50-100 per gram to just $10 per gram, making these life-saving treatments accessible in low-resource settings. - Seven innovative projects are exploring breakthrough approaches including fungal expression systems, continuous flow platforms, and membrane-based purification technologies to replace expensive traditional manufacturing methods. - The initiative targets critical global health needs, with the first application focusing on antimalarial antibodies to address a disease that kills over 500,000 people annually, primarily in Africa. - These cost reduction efforts could transform global access to monoclonal antibody treatments, particularly in low- and middle-income countries where Africa currently holds only 1% of the global mAb market despite high disease burden.
- Researchers at North Carolina State University and University of North Carolina at Chapel Hill developed a self-powered microneedle patch that collects dermal interstitial fluid for biomarker analysis without requiring blood draws or external power sources. - The patch successfully collected measurable biomarker samples in as little as 15 minutes and stored them for at least 24 hours in proof-of-concept testing using synthetic skin models. - The technology targets cortisol monitoring initially but could expand to track glucose, lactate, and inflammation markers, offering a more comfortable and cost-effective alternative to traditional blood testing. - Human testing has begun and the research team is developing companion devices to analyze the collected samples while seeking industry partnerships for commercialization.
- 60 Degrees Pharmaceuticals will submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. - Three independent clinical studies demonstrated that tafenoquine was well tolerated and appeared to facilitate recovery from acute canine babesiosis infection. - Currently no FDA-approved oral treatment exists for canine babesiosis, which affects several hundred to several thousand dogs annually in the United States. - The company's CEO noted that positive canine findings align with earlier research suggesting tafenoquine could be effective against babesiosis in humans.
- A novel formulation of rapamycin has demonstrated the ability to reverse hypertrophic cardiomyopathy (HCM) in cats, marking the first successful treatment for this common feline heart condition. - The drug is expected to receive FDA conditional approval in March 2025, with researchers currently conducting a large-scale pivotal study across 20 US sites involving 300 cats. - Led by Dr. Joshua Stern at NC State, the research shows the drug works by inhibiting the mTOR pathway, potentially transforming HCM treatment from symptom management to addressing underlying pathology.
- The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. - North Carolina State University is exploring a novel treatment approach for oral cancer in cats. - Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. - Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.
